Biodegradable Lung Sealant PEG Hydrogel Patent Granted to Ethicon
Summary
USPTO granted patent US12599624B2 to Ethicon, Inc. for a rapid-setting biodegradable lung sealant comprising two multi-arm polyethylene glycol (PEG) compositions. The first PEG composition contains an alkaline buffer and the second contains a mildly acidic buffer, providing optimized setup time and extended working time. The formulation may include tocopherol as a radioprotectant and a colorant for improved visualization against lung tissue. The patent contains 22 claims and is classified under CPC codes A61K and A61P.
What changed
USPTO granted patent US12599624B2 to Ethicon, Inc. covering a biodegradable lung sealant formulation using high molecular weight (20 kDa) multi-arm PEG compositions with alkaline and mildly acidic buffers. The patent protects configurations with tocopherol radioprotectant and colorant additives for improved surgical visualization.
Ethicon's competitors developing lung sealants or PEG-based surgical adhesives should conduct freedom-to-operate analyses and assess potential licensing needs. Healthcare providers using or procuring lung sealant products should note the strengthened IP position around this technology. The patent provides enforceable exclusivity through the grant date with standard 20-year term from the August 2022 filing date.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Biodegradable lung sealants
Grant US12599624B2 Kind: B2 Apr 14, 2026
Assignee
Ethicon, Inc.
Inventors
Salim A. Ghodbane, Sridevi Dhanaraj, Brian Aitken
Abstract
The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.
CPC Classifications
A61K 31/787 A61K 31/785 A61K 47/22 A61P 11/00
Filing Date
2022-08-30
Application No.
17898897
Claims
22
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.